Literature DB >> 32960107

The high-dose amoxicillin-proton pump inhibitor dual therapy in eradication of Helicobacter pylori infection.

Jianwei Yun1,2, Zhiping Wu1, Guoqing Qi1, Tiyun Han2, Dekui Zhang1,2.   

Abstract

INTRODUCTION: More attention has been paid to the eradication therapy of Helicobactor pylori with the enhancement of health awareness of patients. However, the increasing antibiotic resistance of H. pylori, due to the wide use and abuse of antibiotics, has become a critical factor affecting the efficacy of eradication. To effectively improve the eradication rate of H. pylori, high-dose amoxicillin-proton pump inhibitor (PPI) dual therapy has recently become one of the hot issues. AREAS COVERED: The authors review the schemes and efficacy of high-dose amoxicillin-PPI dual therapies in eradication of H. pylori infection. The review indicates that the H. pylori eradication rate of the dual therapy is overall comparable to or better than that of bismuth-containing quadruple therapy or standard triple therapy. It is more effective to administer both amoxicillin and PPI 3-4 times daily for 14 days in the high-dose amoxicillin-PPI dual therapy, and esomeprazole seems to be superior to other PPIs. EXPERT OPINION: The high-dose amoxicillin-PPI dual therapy is currently a promising H. pylori eradication regimen in clinical practice, deserving further verification and discussion. Much more attention should be paid to the influence of CYP2C19 polymorphisms and virulence genotyping on H. pylori eradication, and the homogeneity and objectivity of the comparison among different studies.

Entities:  

Keywords:  Helicobacter pylori; amoxicillin; eradication therapy; high-dose dual therapy; proton pump inhibitor

Mesh:

Substances:

Year:  2020        PMID: 32960107     DOI: 10.1080/17474124.2021.1826306

Source DB:  PubMed          Journal:  Expert Rev Gastroenterol Hepatol        ISSN: 1747-4124            Impact factor:   3.869


  4 in total

Review 1.  Current guidelines for Helicobacter pylori treatment in East Asia 2022: Differences among China, Japan, and South Korea.

Authors:  Jun-Hyung Cho; So-Young Jin
Journal:  World J Clin Cases       Date:  2022-07-06       Impact factor: 1.534

2.  Comparison of the Dual Therapy of Ilaprazole-Amoxicillin and the Bismuth Quadruple Therapy of Ilaprazole-Amoxicillin-Furazolidone-Bismuth Glycyrrhizinate for Eradication of Helicobacter pylori.

Authors:  Min Niu; Yan Zhou; Yunqian Xie; Xue Li; Yonggang Tian; Li Yao; Ximei Li; Hengjun Gao; Feihu Bai
Journal:  Front Pharmacol       Date:  2022-04-27       Impact factor: 5.810

3.  Effectiveness and Safety of High-Dose Dual Therapy: Results of the European Registry on the Management of Helicobacterpylori Infection (Hp-EuReg).

Authors:  Luis Fernández-Salazar; Ana Campillo; Luis Rodrigo; Ángeles Pérez-Aisa; Jesús M González-Santiago; Xavier Segarra Ortega; Maja Denkovski; Natasa Brglez Jurecic; Luis Bujanda; Blas José Gómez Rodríguez; Juan Ortuño; Sotirios Georgopoulos; Laimas Jonaitis; Ignasi Puig; Olga P Nyssen; Francis Megraud; Colm O'Morain; Javier P Gisbert
Journal:  J Clin Med       Date:  2022-06-20       Impact factor: 4.964

4.  Efficacy and safety of high-dose esomeprazole-amoxicillin dual therapy for Helicobacter pylori rescue treatment: a multicenter, prospective, randomized, controlled trial.

Authors:  Hanxin Bi; Xingxing Chen; Yuxin Chen; Xin Zhao; Shasha Wang; Jiehong Wang; Ting Lyu; Shuang Han; Tao Lin; Mingquan Li; Donghong Yuan; Junye Liu; Yongquan Shi
Journal:  Chin Med J (Engl)       Date:  2022-07-20       Impact factor: 6.133

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.